Back

Cardiac magnetic resonance native skeletal muscle T1 relaxation time is associated with outcome in patients with heart failure with preserved ejection fraction

22 May 2023 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - multi topics Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Christina Kronberger

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
The relationship between echocardiographically assessed E/Em and invasively measured left atrial pressure
Doctor K. Kroupova (Prague, CZ)
Abstract Slides
Presentation thumbnail
Left atrial strain predicts one-year composite clinical outcome in patients with heart failure with preserved ejection fraction
Doctor S. Murat (Eskisehir, TR)
Abstract Slides
Presentation thumbnail
A contemporary comparative analysis between AL and ATTR cardiac amyloidosis and the survival impact of referral to the National Amyloidosis Centre: a UK tertiary centre experience
Doctor L. Khweir (Birmingham, GB)
Abstract Slides
Presentation thumbnail
Lifelong bachelor status is associated with increased mortality in men with heart failure:a secondary analysis of the atherosclerosis risk in communities study
Doctor K. Leyba (Aurora, US)
Abstract Slides
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitors are safe and potentially beneficial for the treatment of heart failure in adult congenital heart disease
Doctor R. Neijenhuis (Leiden, NL)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - multi topics

The Event

Event poster

Heart Failure 2023

22 May 2023 09:00 CET
You may be interested in
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction
thumbnail
Webinar
Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction
thumbnail
Webinar
Acute heart failure in patients with preserved ejection fraction (AHFPEF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources